

AGM Chairman's Address & Post Meeting Shareholder Presentation

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**), is pleased to provide a written version of the Non-Executive Chairman's Address to be provided by Mr Otto Buttula and the Shareholder Presentation to be provided by Dr David Atkins to shareholders at the Annual General Meeting to be held in Melbourne commencing at 12:00 pm AEDT today.

Chairman's Address

Good afternoon shareholders and service providers, I am pleased to welcome you all to the 2024 Annual General Meeting of Rhythm Biosciences Limited.

It is now just after 12.00pm AEDT and with the meeting having been properly constituted, I have also been advised that a quorum of members is present, therefore I declare the meeting open for business. My name is Otto Buttula and as the Company's Non-Executive Chairman, I will be presiding over today's meeting.

Today in the room, I am pleased that our current directors have been able to make it here in-person and we also have our previous directors who have retired effective this morning. From our current Board, apart from myself, we have, sitting to my left:

- Ms Sue MacLeman – who will retire as Independent Deputy Chair, effective 2 December 2024, following my return as at the end of May to a Non-Executive status and with Mr Gavin Fox-Smith joining the Board on that date;

We also have, our Chief Executive Officer, who joined the Board as Managing Director as of 30 September this year:

- Dr David Atkins.

As alluded to, we also have with us our recently retired directors, being:

- Dr Trevor Lockett, previously our first CEO and Managing Director and following which Executive Technical Director until the end of 2023; and
- Mr Lou Panaccio – previously a Non-Executive Director, who also joined the Company, prior to its initial public offering in late 2017.

Also, in attendance are our Joint Company Secretaries, Mr James Barrie and Ms Andrea Steele.

I would also like to thank Mr Tony Batsakis from our audit partner, BDO for attending today to answer any shareholder queries in relation to the audit or the audit report.

We also have Mr Andrew Gaffney from K&L Gates, whose office we are utilising today and Mr Michael Port and Mr James Barci from our external accountants, DFK Kidsons. I would also like to welcome some of our Rhythm Team who are in attendance today and who continue to drive the Company towards achieving commercialisation of its IP portfolio, which in the first instance is intended to be through our revised version of ColoSTAT®.

The Notice of Meeting and the Explanatory Notes have been circulated in accordance with the requirements set out in the Company's Constitution, and I take these as having been read.

I am advised valid proxies have been received from 117 shareholders, representing 108,559,159 shares or 43.0% of the issued capital of the Company.

Minutes of the Company's previous Annual General Meeting held on 10 October 2023 are available for inspection by any member wishing to do so.

Before we move to the formal items of business, I would like to make some opening comments.

Rhythm makes a significant commitment to diversity, by accepting and respecting different points of view and leveraging them to learn from one another. Our small team has demonstrated an exceptional willingness to collaborate, engage and execute.

In regard to our business, the last year was unfortunately one again in which we disappointed, with a significant and ongoing decrease in our share price and one in which we failed to commercialise our initial and lead product ColoSTAT®, largely due to internal missteps. Despite these past failures, the Board remains confident about the Company's prospects in 2025 and beyond. But rather, than me pontificating about such, I will, post today's formal business matters being concluded, hand over to David to provide a short update presentation.

As you would also have seen, we have just announced a successful capital raising totalling \$3.5 million, ex-costs, welcoming largely new institutional and sophisticated investors. This placement gives funding certainty allowing our management team scope to accelerate activities.

Before moving to the formal business, on behalf of the Board, I would sincerely like to thank our staff members, most of whom are new and have provided renewed energy and vigour and are determined to succeed on previously built foundations. I also would like to recognise our loyal and patient shareholders for their ongoing commitment. We look forward to keeping you, our fellow owners up to date with our progress towards our objectives and achievements throughout 2025, a year in which we believe we can deliver several milestone achievements which should result in a return to growth and value appreciation.

Thank you, we will now proceed to the formal business as set out in the Notice of Meeting.

- ENDS -

Authorised for release by the Board.

For further information contact us via investors@rhythmbio.com:

Dr David Atkins Chief Executive Officer	Ms Andrea Steele Joint Company Secretary & General Counsel
---	--

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.



Post-AGM Investor Presentation

20 NOVEMBER 2024

Disclaimer

This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

Executive Summary



Overview

- Rhythm Biosciences is developing and commercialising novel clinical cancer diagnostics.
 - ColoSTAT® is a 2nd generation multiplex assay designed to detect bowel cancer in a patient blood sample that is in the final stages of development ahead of commercialisation in 2025.
-

Key Investment Highlights

- Accelerated market entry strategy into a multi \$bn global market.
 - RHY Cancer diagnostic solutions are clearly differentiated from competition: reduced invasiveness, ease of use, patient preferred and cost.
-

Transformed Business

- Building on valuable Company learnings with new internal and external capabilities and enhanced commercial focus.
 - Complete re-engineering of core assay technology delivers customer requirements.
 - Pragmatic, quicker and lower risk path to market identified.
-

Why Rhythm Biosciences?

Rhythm Biosciences is committed to saving lives through early detection of cancers using simple and accurate diagnostic technology.

Developing novel screening solutions for specific cancers via patient friendly blood tests is our primary focus.

Patent protected; fully characterised technology that can be readily adopted in all laboratories.

Targeting large global markets heavily supported by public and private health care systems.

Competitive product design that supplements and potentially improves current standard cancer testing methods used around the globe.

ColoSTAT[®]: A novel product with anticipated commercial launch in 2025.



Corporate overview



CORPORATE SNAPSHOT

ASX Code	RHY
Share Price (at 15 Nov 2024)	\$0.115
Shares on Issue	248.5M
Unlisted Options	21M
Market Capitalisation	\$28.58M
Top 20 Shareholders	42%

SHARE PRICE CHART - ASX:RHY



BOARD AND MANAGEMENT

David Atkins, PhD

Chief Executive Officer and Managing Director



Former CEO of Congenica (UK) & Synevo Diagnostics, Sr. Executive at Johnson & Johnson and Danaher.

Founder of Veridex – cancer molecular and cellular diagnostics (USA).

Significant experience in fund raising and VC investing. Currently adviser and board member for several private oncology businesses in UK and EU.

Otto Buttula

Non-Executive Chairman



Extensive financial, investment, IT & biotech experience.

Co-Founder and CEO of IWL (ASX: IWL); Founder / former CEO of Investors Mutual.

Formerly a Director of Imugene (ASX:IMU), Chairman of Investorfirst, now HUB (ASX: HUB), HITIQ (ASX: HIQ) & Oncosil Medical (ASX: OSL).

Sue MacLeman

Non-Executive Independent, Deputy Chair



30 years in Pharma, Biotech and Medtech including Amgen, BMS and Merck.

Experienced Board member, former CEO of NASDAQ, ASX, & AIM entities. Currently NED at Health Translation Group Ltd, Viral Vector Manufacturing Facility, Smartways Logistics, ATSE & OMICO & member of various government & academic advisory committees.

Trevor Lockett, PhD

Non-Executive Director



Former Theme Leader Colorectal Cancer and Gut Health CSIRO.

Leader – Personalised Health Group CSIRO.

Inventor on seven commercially-licensed patent families.

Lou Panaccio

Non-Executive Director



Chairman of Avita Medical (ASX: AVH) and Adherium Ltd (ASX:ADR).

Non-Executive Director Sonic Healthcare (ASX: SHL) and Unison Housing.

Former CEO Melbourne Pathology & Monash IVF.

Our Clinical Advisory Board



**Sally
Benton**

Consultant Clinical Biochemist and Clinical Lead for Clinical and Specialist Biochemistry Services at Berkshire and Surrey Pathology Services, a pathology network that serves 6 acute hospitals. Sally is also Director of the Bowel Cancer Screening South England Hub based at the Royal Surrey County Hospital, Guildford, serving a total population of about 16 million people across the South of England.



**Prof
Jon Emery**

Herman Professor of Primary Care Cancer Research at the University of Melbourne, and the Victorian Comprehensive Cancer Centre (VCCC) Primary Care Research and Education Lead. He is a National Health and Medical Research Council (NHMRC) Leadership Fellow, and Director of the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4).



**Prof
Finlay Macrae**

Head of Colorectal Medicine and Genetics at The Royal Melbourne Hospital, he is a lead clinician in the Familial Cancer Clinic and is engaged in research into Colorectal Cancer genetics and new therapies for Inflammatory Bowel Disease (IBD).

He trained in London with the world's leading colonoscopist at the time (St Mark's Hospital) and brought this skill to Australia and his practice.

When diagnosed early, CRC can be successfully treated

Disease stage at diagnosis is the key predictor of survival in patients with CRC

Diagnoses at Stage I or II only represent less than half of all CRCs diagnosed in:

	Stage I	Stage II
 AUSTRALIA	22% 	23% 
 US	37% 	37% 
 UK	16% 	21% 

Abbreviations: CRC, colorectal cancer; US, united States
References: can be provided

Missed detection of early-stage CRC results in poor survival rates




5-year survival rates in patients with CRC in US, UK and Australia

Participation in CRC screening programs needs improvement

Based on current participation rates to CRC screening, **33–56% of the eligible population** across Australia, Europe, UK and US **remains unscreened**.

Participation rates in CRC screening programmes in UK, US, Europe and Australia (2018/2019/2021).



As many as **53.7 million** eligible people across US, UK and Australia **remain unscreened** for CRC.

Abbreviations: CRC, colorectal cancer; FIT, faecal immunochemical test

† Percentage of adults aged ≥50 years who had colonoscopy in the past 10 years (2018 data).

†† Percentage of people aged 60–74 year screened for CRC with FIT in 2020/2021.

‡ Percentage of people screened for CRC with FIT in 12 European Union Member States in 2018.

§ Based on 2020 UK population aged 60–74 years of 10.57 million and on 33.2% of the eligible population not been screened for CRC (participation rate: 66.8%).

†† Based on 2021 US population aged ≥50 years of 115.62 million and on 39.0% of the eligible population not been screened for CRC (participation rate: 61.0%).

Based on 2021 Australia population aged 50–74 years of 7.08 million and on 56.5% of the eligible population not been screened for CRC (participation rate: 43.5%).

There are >250 million people who could benefit from an improved blood test



MARKET	POPULATION	AGE – SCREENING POPULATION	SCREENING METHOD	SCREENING PARTICIPATION RATE	UNSCREENED POPULATION/ OPPORTUNITY	INCIDENCE OF CRC (cases per year)	% OF TOTAL ADDRESSABLE MARKETS
Europe (EU-27)	746.4 m	231.0 m (50 -74 yrs)	FIT, Colonoscopy [†]	38%	143.0m	341,419	62%
UK (England, Scotland, Wales and Northern Ireland)	67.6 m	10.6 m (60 -74 yrs)	FIT	67%	3.5m	52,128	33%
USA	331.9 m	161.5 m (45 – 75+ yrs)	FIT, Colonoscopy, Cologuard	61%	62.9m	153,020	
Japan	125.7 m	60.2 m (> 40 yrs)	FIT	20% [¥]	48.0m	148,505	80%
South Africa	59.4 m	9.3 m (50 -74 yrs)	FIT	NA		8,671 ^{**}	
Australia	25.7 m	7.1 m (50 – 74yrs)	FIT	43%	4.0m	15,713	56%
New Zealand	5.1 m	1.1 m (60 -74 yrs)	FIT	57% [*]	0.5m	> 3,000	
Total		480.8m			262.1m		

* Based on pilot project, recent data not available - <https://www.health.govt.nz/our-work/preventative-health-wellness/screening/bowel-screening-pilot/bowel-screening-pilot-results>

** https://journals.lww.com/ajg/Fulltext/2021/10001/S342_Evaluating_Trends_of_Colorectal_Cancer.342.aspx

¥ Needs further investigation

† Every 10 years

FIT; faecal immunochemical test, NA; not available

First major clinical performance evaluation

Prospective, multi-centre study to evaluate the clinical performance of the first generation ColoSTAT[®] for the detection of CRC¹

STUDY DESIGN

Blood-based assay

N= 989 patients, aged 40 to <85.

PRIMARY ENDPOINT

The primary endpoint was to evaluate ColoSTAT[®] performance compared to gold standard, colonoscopy.

RESULTS

ColoSTAT[®] met the primary endpoint and showed a high-sensitivity blood test for CRC detection.

ColoSTAT[®] may provide an alternative test for people who cannot or will not take the FIT test.

Sensitivity¹

81%

Specificity¹

91%


CRC; colorectal cancer, FIT; faecal immunochemical test

1. He et al DOI: 10.1200/JCO.2023.41.16_suppl.3529



Second generation ColoSTAT[®] clinical assay

Standardised, simpler, faster turnaround time and lower cost




Laboratory customers prefer the design of the new ColoSTAT[®] assay design.

General population screening for CRC remains the ultimate goal

Targeting “intermediate” applications represent valuable intermediate steps towards the end goal

‘Intermediate’ Means

- Higher prevalence of cancer.
- Greater flexibility around current standard of care (SoC).
- Clear economic benefit.
- An opportunity to insert the new assay into the current SoC.



Note: Size of circles and relative position is not quantitative, and positions are for the purpose of illustration

Upcoming value inflection points

ITEM	DESCRIPTION	ESTIMATED DELIVERY DATE
Alpha Assay Ready	Arrival of Alpha kits for testing	
Beta Release Candidate	Beta Kits ready for verification	2H CY24
Kit Validation Ready	Kit Verification completion, Production Kits Ready.	1H CY25
Commercialisation	Partner's In House IVD launch	2H CY25

Platform technology expansion pipeline

Biomarker analysis complete in significant patient sample study for 3 major cancers



STAGE 1 PROGRESSION		THEORETICAL ANALYSIS OF BIOMARKER POTENTIAL	SERUM AND ALGORITHM ANALYSIS	RISK ANALYSIS → ENTER STAGE 2
CANCER TYPE	COLLABORATOR			
Breast	Agilex Biolabs			
Lung	Baker Institute			
Gastric	Nexomics			
Cervical	ON HOLD			
Pancreatic	ON HOLD			

Lung cancer blood-based assays will be the next priority.

Placement Issue Offer

Key details of the Offer	
Placement Offer	New Share Issue, plus • 2 New Options (ASX: RHYO) for every 3 New Shares subscribed under the Offer; and • Additional, new ASX Listed Options to purchase a Share with an exercise price of \$0.20 and an Expiry Date of 31 March 2026 (subject to Shareholder Approval)
Issue Price per New Share	\$0.10 or 10 cents per New Share payable in full on Application
Maximum number of New Shares issued under the Offer	35,000,000 New Shares
Maximum proceeds from the Offer (excluding costs associated with the Offer)	\$3.5 million (before expenses and costs of the issue)
Maximum number of Shares on issue following the Offer (refer to Section 3 below)	289,596,750 Shares

Use of Funds

Use of funds	
Progress Product Development – 2nd Generation ColoSTAT®. <i>Complete development and production of ColoSTAT ® Multiplex test kits in conjunction with product development partner in North America.</i>	Up to \$0.70m
Clinical Validation Program and preparation regulatory approvals. <i>Clinical validation activities, including serum sample collection across sites and laboratory testing. Development of strategy and materials for regulatory agency submission.</i>	Up to \$1.20m
Continued R&D pipeline development activities into other cancers <i>Further funds allocated to R&D in progressing studies into other cancers.</i>	Up to \$0.25m
General Working Capital and capital raising costs <i>Day to day working capital requirements and capital raising costs for the Offer</i>	Up to \$1.35m
Maximum funds raised under the Offer	Up to \$3.5m

Indicative Timetable of the Offer

Event	
Prospectus Date	Tuesday, 19 November 2024
Closing Date	Tuesday, 19 November 2024
Issue of the New Shares	Wednesday, 27 November 2024
Trading (T+2) of New Shares expected to commence	Friday, 29 November 2024
Issue of the New Options (subject to Shareholder Approval)	January – February 2025
Trading (T+2) of New Options expected to commence (subject to Shareholder Approval)	January – February 2025

* The above dates are indicative only and subject to change. The Company reserves the right, subject to the Corporations Act and the Listing Rules, to extend the Closing Date or to withdraw the Offer at any time without prior notice, in which case all Application Monies will be refunded (without interest) as soon as practicable. Any extension of the Closing Date will have a consequential effect on the issue date of New Shares. All dates and times are references to Melbourne, Australia time.


Theoretical Value of Options

Placement Issue Offer Discount		
Current share price (at 14 November 2024)	\$0.1150	\$0.400
Rights Issue offer	\$0.1000	
Discount	13.0%	

Discount vs Volume Weighted Average (VWAP) Share Price (ASX)	
5-day VWAP - discount 19.5% #	\$0.1224
15-day VWAP - discount 11.4% #	\$0.1256

Theoretical Offer of Options* / Effective Entry Price	
Theoretical Value of Option (31 Mar 2026)	\$0.0355
Theoretical Value of Option Adjusted ~	\$0.0237
Rights Issue Offer	\$0.1000
Theoretical New Issue Price (deducting Value of the Option, per New Share subscribed for)	\$0.0763

Volume Weighted Average Price (VWAP) using ASX prices only to 14 November 2024..
 ~ Adjusted Option Value as 2 Options for 3 Shares. Source: RHY & Black & Scholes Model.



Conclusion

Overview

Final stages of developing a potential “blockbuster” diagnostic product targeting a multi-\$billion global market.

Key Investment Highlights

An attractive and comparatively simple investment proposition / business model.

Transformed Business

A business with huge potential that has gone through a significant and productive business transformation.
